 | Up a level |
Rossing, Peter; Garweg, Justus G; Anker, Stefan D; Osonoi, Takeshi; Pitt, Bertram; Rosas, Sylvia E; Ruilope, Luis Miguel; Zhu, Dalong; Brinker, Meike; Finis, David; Leal, Sergio; Schmelter, Thomas; Bakris, George (2023). Effect of finerenone on occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). Diabetes, obesity & metabolism, 25(3), pp. 894-898. Wiley 10.1111/dom.14915
Garweg, Justus G; Štefanickova, Jana; Hoyng, Carel; Niesen, Tobias; Schmelter, Thomas; Leal, Sergio; Sivaprasad, Sobha (2022). Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Advances in therapy, 39(6), pp. 2701-2716. Springer 10.1007/s12325-022-02119-z
Mitchell, Paul; Holz, Frank G; Hykin, Philip; Midena, Edoardo; Souied, Eric; Allmeier, Helmut; Lambrou, George; Schmelter, Thomas; Wolf, Sebastian (2021). Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study. Retina, 41(9), pp. 1911-1920. Wolters Kluwer 10.1097/IAE.0000000000003128
Korobelnik, Jean-François; Larsen, Michael; Eter, Nicole; Bailey, Clare; Wolf, Sebastian; Schmelter, Thomas; Allmeier, Helmut; Chaudhary, Varun (2021). Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study. American journal of ophthalmology, 227, pp. 106-115. Elsevier Science 10.1016/j.ajo.2021.01.027
Joussen, Antonia M; Wolf, Sebastian; Kaiser, Peter K; Boyer, David; Schmelter, Thomas; Sandbrink, Rupert; Zeitz, Oliver; Deeg, Gesa; Richter, Annett; Zimmermann, Torsten; Hoechel, Joachim; Buetehorn, Ulf; Schmitt, Walter; Stemper, Brigitte; Boettger, Michael K (2019). The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial. British journal of clinical pharmacology, 85(2), pp. 347-355. Wiley-Blackwell 10.1111/bcp.13794
